» Articles » PMID: 37199147

Shorter Door-to-Needle Times Are Associated With Better Outcomes After Intravenous Thrombolytic Therapy and Endovascular Thrombectomy for Acute Ischemic Stroke

Abstract

Background: Existing data and clinical trials could not determine whether faster intravenous thrombolytic therapy (IVT) translates into better long-term functional outcomes after acute ischemic stroke among those treated with endovascular thrombectomy (EVT). Patient-level national data can provide the required large population to study the associations between earlier IVT, versus later, with longitudinal functional outcomes and mortality in patients receiving IVT+EVT combined treatment.

Methods: This cohort study included older US patients (age ≥65 years) who received IVT within 4.5 hours or EVT within 7 hours after acute ischemic stroke using the linked 2015 to 2018 Get With The Guidelines-Stroke and Medicare database (38 913 treated with IVT only and 3946 with IVT+EVT). Primary outcome was home time, a patient-prioritized functional outcome. Secondary outcomes included all-cause mortality in 1 year. Multivariate logistic regression and Cox proportional hazards models were used to evaluate the associations between door-to-needle (DTN) times and outcomes.

Results: Among patients treated with IVT+EVT, after adjusting for patient and hospital factors, including onset-to-EVT times, each 15-minute increase in DTN times for IVT was associated with significantly higher odds of zero home time in a year (never discharged to home) (adjusted odds ratio, 1.12 [95% CI, 1.06-1.19]), less home time among those discharged to home (adjusted odds ratio, 0.93 per 1% of 365 days [95% CI, 0.89-0.98]), and higher all-cause mortality (adjusted hazard ratio, 1.07 [95% CI, 1.02-1.11]). These associations were also statistically significant among patients treated with IVT but at a modest degree (adjusted odds ratio, 1.04 for zero home time, 0.96 per 1% home time for those discharged to home, and adjusted hazard ratio 1.03 for mortality). In the secondary analysis where the IVT+EVT group was compared with 3704 patients treated with EVT only, shorter DTN times (≤60, 45, and 30 minutes) achieved incrementally more home time in a year, and more modified Rankin Scale 0 to 2 at discharge (22.3%, 23.4%, and 25.0%, respectively) versus EVT only (16.4%, <0.001 for each). The benefit dissipated with DTN>60 minutes.

Conclusions: Among older patients with stroke treated with either IVT only or IVT+EVT, shorter DTN times are associated with better long-term functional outcomes and lower mortality. These findings support further efforts to accelerate thrombolytic administration in all eligible patients, including EVT candidates.

Citing Articles

Mechanical thrombectomy for acute ischemic stroke performed without continuous saline flushes and using moderate sedation: The TOOFAST technique.

Porto C, Teshome A, Feler J, Moldovan K, Fontanez S, Torabi R Interv Neuroradiol. 2025; :15910199251323010.

PMID: 40017401 PMC: 11869227. DOI: 10.1177/15910199251323010.


Migraine and stroke: correlation, coexistence, dependence - a modern perspective.

Boronczyk M, Zdunska A, Wegrzynek-Gallina J, Grodzka O, Lasek-Bal A, Domitrz I J Headache Pain. 2025; 26(1):39.

PMID: 39979846 PMC: 11844069. DOI: 10.1186/s10194-025-01973-w.


Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial.

Lee J, Kang H, Ahn S, Song T, Shin D, Bae H JAMA Netw Open. 2025; 8(1):e2456535.

PMID: 39874036 PMC: 11775734. DOI: 10.1001/jamanetworkopen.2024.56535.


Association Between CT With Angiography and 30-Day Risk of Stroke or Transient Ischemic Attack in a Canadian Emergency Department Setting.

Jacob J, Rashid U, Lee C, Menon B, Lin K Cureus. 2024; 16(11):e74041.

PMID: 39712768 PMC: 11659187. DOI: 10.7759/cureus.74041.


Harnessing micrometer-scale tPA beads for high plasmin generation and accelerated fibrinolysis.

Osmond M, Dabertrand F, Quillinan N, Su E, Lawrence D, Marr D bioRxiv. 2024; .

PMID: 39574757 PMC: 11580863. DOI: 10.1101/2024.11.06.621942.


References
1.
Hammill B, Hernandez A, Peterson E, Fonarow G, Schulman K, Curtis L . Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J. 2009; 157(6):995-1000. PMC: 2732025. DOI: 10.1016/j.ahj.2009.04.002. View

2.
Meinel T, Kaesmacher J, Buetikofer L, Strbian D, Eker O, Cognard C . Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial. J Neurointerv Surg. 2022; 15(e1):e102-e110. PMC: 10715486. DOI: 10.1136/jnis-2022-019207. View

3.
Zi W, Qiu Z, Li F, Sang H, Wu D, Luo W . Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. JAMA. 2021; 325(3):234-243. PMC: 7816099. DOI: 10.1001/jama.2020.23523. View

4.
Mishra N, Shuaib A, Lyden P, Diener H, Grotta J, Davis S . Home time is extended in patients with ischemic stroke who receive thrombolytic therapy: a validation study of home time as an outcome measure. Stroke. 2011; 42(4):1046-50. DOI: 10.1161/STROKEAHA.110.601302. View

5.
Cumbler E, Wald H, Bhatt D, Cox M, Xian Y, Reeves M . Quality of care and outcomes for in-hospital ischemic stroke: findings from the National Get With The Guidelines-Stroke. Stroke. 2013; 45(1):231-8. DOI: 10.1161/STROKEAHA.113.003617. View